血液国际谈丨Arnaud Pigneux教授：法国创新白血病组织（FILO）AML治疗成果分享——洛莫司汀与雄激素疗法的创新实践

（上下滑动查看英文原文）

Oncology Frontier-Hematology Frontier： What specific cases or achievements can you share about FILO's contributions to innovative leukemia treatments? How have these innovations improved patient outcomes and quality of life?

Professor Arnaud Pigneux： The federal group in the past years has improved the outcome of the ML patients in two ways. The first was by adding a third drug to induction chemotherapy, this drug is lomustine or CCNU and it permits to improve the survival and the complete remission for patients.

The second way was that, I think we improve the result was by adding androgen therapy for maintenance. The name of the drug was neither var nor is on the road. Unfortunately, it's not produced for the wide and we tried to have a new production of this drug. It is very important to hurry up maintenance. I think we have to input some more drugs in this part of treatment.

（上下滑动查看英文原文）

Oncology Frontier-Hematology Frontier： What strategies has FILO adopted to address challenges in leukemia treatment, such as drug resistance? How effective have these strategies been?

Professor Arnaud Pigneux： Nowadays, we tried to work as a European group, because as you know, ML is now a multiple disease with the targeted therapies we can use. So we have worked with the HOVON and AMLSG group for targeted therapy against the FLT3 and IDH. And we are searching for new strategies for other target like Menin inhibitors. In the future, maybe other countries in Europe.